In:
Clinical Transplantation, Wiley, Vol. 29, No. 4 ( 2015-04), p. 359-364
Abstract:
B cells and their regulation by B‐cell activating factor BAFF are of growing interest in kidney transplantation ( KT x). There is evidence that high serum (s) BAFF leads to increased allosensitization and impaired long‐term graft function. We prospectively investigated sBAFF , peripheral blood lymphocytes ( PBL ), and donor‐specific HLA antibodies ( DSA ) in patients after ABO i with B‐cell depleting rituximab induction treatment and compared them to a group of blood group‐compatible ( ABO c) living donor kidney recipients. Twelve patients after ABO i and 18 after ABO c were included. After rituximab treatment prior to ABO i, B cells remained significantly lower 1 year after KT x (1.2% (0.0–17.8) compared to ABO c of 8.6% (2.8–35.0), p = 0.0004 , and also BAFF ‐R expression was significantly lower in ABO i (p 〈 0.006) . sBAFF remained elevated 1 year post‐Tx compared to ABO c (3615 ± 1800 vs. 1394 ± 493 pg/mL, p 〈 0.004) . Kidney function was not significantly different between both groups after 1, 2, and 3 years. The use of rituximab in ABO i together with maintenance immunosuppression leads to significant elevation of sBAFF and lowering of B‐cell numbers for more than 1 year, and this does not correlate with worse 3‐year graft outcome.
Type of Medium:
Online Resource
ISSN:
0902-0063
,
1399-0012
DOI:
10.1111/ctr.2015.29.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2739458-X
detail.hit.zdb_id:
2004801-4
Permalink